Blue Owl Capital Holdings »

Black Diamond Therapeutics shares owned by Blue Owl Capital Holdings

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Blue Owl Capital Holdings from 13F filings

Historical chart of Blue Owl Capital Holdings investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Blue Owl Capital Holdings consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Blue Owl Capital Holdings

Quarter filed Position value Share count Share price at filing
2023-12-31 $2.0M 695k 2.81

More positions owned by Blue Owl Capital Holdings

Pliant Therapeutics (PLRX)
Robinhood Mkts Com Cl A (HOOD)
Cullinan Oncology (CGEM)
Tourmaline Bio (TRML)
Klaviyo Com Ser A (KVYO)
Owl Rock Capital Corporation (OBDC)
Repare Therapeutics Ord (RPTX)
Acelyrin (SLRN)
Larimar Therapeutics (LRMR)
Keros Therapeutics (KROS)
Ultragenyx Pharmaceutical (RARE)
Engene Holdings (ENGN)
Syros Pharmaceuticals Com New (SYRS)
Disc Medicine (IRON)
E2open Parent Holdings Com Cl A (ETWO)

View all positions for Blue Owl Capital Holdings

Top funds holding Black Diamond Therapeutics

Bellevue Group
NEA Management Company
RA Capital Management
Artal Group
Vanguard Group
Tang Capital Management
Jpmorgan Chase & Co
Kennedy Capital Management
Blue Owl Capital Holdings
Ikarian Capital
Candriam Luxembourg S.C.A.
Boxer Capital
Two Sigma Investments
Newtyn Management
Barclays

View all funds holding Black Diamond Therapeutics